In NSCLC A549 cells, TGF-β or ginsenosides Rk1 and Rg5 treatment inhibits the Smad and NF-kB/ERK pathways (non-Smad pathway) to control EMT in a dose-dependent way (527). Here, TGFB1 is linked to non-small cell lung carcinoma.